Biopharmaceutical development and manufacturing demand scalable processes that can be smoothly transferred to production. These processes need to be quickly developed and easy to implement. Ready-to-use technologies such as the ReadyToProcess™ platform from GE Healthcare Life Sciences play a crucial role in providing the flexibility to support multiproduct facilities and deliver process time savings, allowing for faster changeover between products. The ReadyToProcess platform is a complete suite of preconditioned systems and accessories for biopharmaceutical production, prepared for immediate use. The platform includes both single-use and reusable products.
Single-use technologies offer an attractive option for biopharmaceutical manufacturing, but their environmental impact needs be considered. This paper documents the findings of an extensive LCA study comparing single-use and conventional bioprocessing technology for the production of monoclonal antibodies (MAbs).